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Background: Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasm affecting the
gastrointestinal tract. The incidental occurrence of mesenchymal tumors and other primary tumors has
not been well described in literature.
Objective: The aim of this study was to evaluate the clinical and pathologic features of GIST occurring
synchronously with other primary tumors.
Methods: Forty-three patients with diagnosis of GIST treated surgically with curative intent at our insti-
tution from 1998 to 2006 were included. The patient clinical data and pathological reports were reviewed.
Results: Of the 43 patients, there were 6 (14%) cases of synchronous GIST and other primary tumors
discovered as coincidental ﬁndings. The synchronous GISTs analyzed were located in the stomach (50%)
and small intestine (50%), size ranging from 0.7 to 7.6 cm (median 3.35 cm). Five (83%) of the concurrent
primary tumors were from gastrointestinal origin and only one (17%) patient presented with concurrent
breast cancer and GIST. The synchronous GISTs immunofenotype shows positivity for CD117 and CD34
(100%), smooth-muscle actin (SMA) (67%), S100 (50%) and desmin (33%). Whereas staining for cyto-
keratin AE1/AE3 and PDGF were all negative. According to GIST risk category for aggressive behavior
three were classiﬁed as very low, one intermediate and two high.
Conclusions: The synchronous occurrence of GISTs and other primary neoplasm is not an uncommon
entity and usually they are discovery incidentally. Epithelial tumors of the gastrointestinal tract are the
most associated with concomitant GISTs. Further studies are required to clarify the molecular and genetic
mechanisms of carcinogenesis and progression associating GIST and synchronous tumors.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal
neoplasms affecting the gastrointestinal tract.1e3 These tumors
have a wide clinical spectrum from benign, small, incidentally
detected nodules to frankly malignant tumors.4 The synchronous
occurrence of GISTs and other primary tumors is considered anOncology, Pontiﬁcal Catholic
Hospital, Av. Ipiranga 6690,
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ciates Ltd. Published by Elsevier Ltuncommon entity however such occurrence has been more
frequently described in literature mainly in form of single case
reports.5e18 KIT and PDGFRA activating mutations are the onco-
genic mechanisms in most sporadic and inherited GISTs. Little is
known about the possible mechanisms involved in synchronous
GIST and other neoplasms, some syndromic or familial disease are
suspected in the presence of second primary tumor and C-KIT and
PDGFRA negative GIST patients.19 Synchronous occurrence of GIST
and other tumors are almost always discovered incidentally as
during surgery or staging exams of the primary disease.
In this study, we introduce a series of six patients, from a single
institution, with GIST and a second primary neoplasm occurring
synchronously. The aim of this study was to evaluate the clinical
and pathologic features of GISTs occurring synchronously with
other primary tumors.d. All rights reserved.
Table 1
Patient characteristic with GIST and other primary tumors characteristic.
Patient number Age Gender Synchronous primary tumor localization
1 36 F Colon
2 52 M Gastric
3 65 F Gastric
4 65 F Esophagus
5 69 F Colon
6 79 F Breast
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2.1. Patients
Forty-three patients diagnosed with GIST from January 1998
and September 2006 treated surgically with curative intent at
Hospital São Lucas-PUCRS (Porto Alegre, Brazil) was included.
Clinical records and pathologic reports were reviewed in each case.2.2. Histogical and immunohistochemistry analyses
The histological diagnosis of all GISTs had been conﬁrmed at the
Department of Pathology of Hospital São Lucas-PUCRS. Specimens
were ﬁxed in 10% formaldehyde and processed routinely for
parafﬁn embedding. 3-mm-thick sections were stained with hem-
atoxilyn-eosin. Mitoses were counted in 50 high-power ﬁelds.
Immunohistochemistry was performed in all stromal tumors
using a panel of commercially available antibodies direct against
the following antibodies: CD117 (polyclonal; Dako, Glostrup,
Denmark), CD34 (monoclonal; clone QBEND-10; Ylem, Rome,
Italy), Desmin (monoclonal; clone D33; Biogenex, San Ramon,
USA), S-100 protein (polyclonal; Dako, Glostrup, Denmark),
smooth-muscle actin - SMA (monoclonal, clone 1A4; Dako,
Glostrup, Denmark), cytokeratin cocktail antibody AE1/AE3
(polyclonal; Dako, Glostrup, Denmark), Ki67 (monoclonal; clone
MM1; Novocastra, UK) and PDGF-ß (polyclonal; DakoCytomation,
Carpinteira, USA). ABC (Dako, Glostrup, Denmark) was the
detection system, and DAB Substrate (Merck, WS, NJ, USA) was the
chromogen.3. Results
From the 43 patients with GIST treated in our department 28
(65%) were female and 15 (35%) male, the median age at the
diagnosis was 62 years old (range 22e83). The GISTs were diag-
nosed on the stomach (53%), small bowel (35%), large bowel (5%)
and mesentery (7%). The tumor size varied from 0.4 to 30 cm
(median 7.4 cm). Immunohistochemistry performed in these
tumors showed diffuse strong positivity for CD117 in 40/43 cases
(93%) and CD34 in 24/34 cases (70%).
In our study, GIST occurred synchronously with other neoplasm
in 6 (14%) patients. The concomitant cases were primary tumorsTable 2
Pathological characteristics of synchronous GIST and the other primary tumors.
Patient number GIST Sync
Localization Size (cm) Type
1 Small intestine 5.0 Aden
2 Gastric 1.1 Aden
3 Gastric 0.7 Aden
4 Gastric 0.7 Carc
5 Small intestine 5.0 Aden
6 Small intestine 7.6 Invaand during the planned treatment, such as CT scanning or surgery,
GIST was discovered as an incidental ﬁnding. From the synchronous
neoplasms, ﬁve (83%) had gastrointestinal origin and only one (17%)
presented with breast cancer. With the exception of the breast
cancer patient all others GISTs were an incidental ﬁnding during
the surgery for other primary tumors, where 50% of these were
located in the stomach and other 50% were in the small intestine.
The clinical characteristics of patients with synchronous tumors are
shown in Table 1.
The synchronous GISTs analyzed were located in the stomach
(50%) and small intestine (50%), size ranging from 0.7 to 7.6 cm
(median 3.35 cm). The pathologic features of synchronous GISTs
and other primary tumors are summarized in Table 2.
Regarding the treatment, GISTs were resected by enterectomies
(n¼ 3) in 2 cases discovered during colectomy for colorectal cancer
and 1 case found incidentally in an abdominal Computed Tomog-
raphy (CT) for breast cancer staging. Partial and total gastrectomy
(n¼ 2) was performed for gastric cancer and in this case GIST was
discovered during the histopathological examination. Esoph-
agogastrectomy (n¼ 1) was the treatment for esophageal cancer
and concomitant GIST in the stomach diagnosed by esophagogas-
troduodenoscopy. Macroscopically all GISTs presented as nodular
mass and were dissected with clear margins.
All synchronous GISTs were uniformly CD117 and CD34 positive.
Smooth-muscle actin (SMA) was detected in four (67%) cases, S100
in three (50%) and desmin in two cases (33%). Whereas staining for
cytokeratin AE1/AE3 and PDGF were negative for all GISTs studied.
In addition to the immunophenotype, the tumor size and mitotic
index reveal that the synchronous GISTs could be classiﬁed as very
low (n¼ 3), intermediate (n¼ 1) and high (n¼ 2) risk of aggressive
behavior.20 The histopathologic features of the synchronous GISTs
are shown in Table 3.4. Discussion
GIST is a rare neoplasm that represents about 0.1e1.0% of all
malignant neoplasms of the gastrointestinal tract. Most GISTs arise
from the stomach (50e62%), the small intestine (20e30%), the
colon (11%) and the rectum (7%), while the esophagus is rarely
involved (0.6e1%).3,4,18,21 They also have been found in others
locations such as the omentum, mesentery and retro-
peritoneum.21,22 In our series, there were 14% (6/43) cases of
synchronous occurrence of GIST and other gastrointestinal malig-
nancies, which is in the average incidence of 10 to 35% described in
the literature.7,18,22e25 GISTs have been reported to occur synchro-
nously mostly with adenocarcinoma, in our series 83% (5/6) had
this histology, nevertheless there are reports of synchronicity with
lymphomas and carcinoid tumors.7,26 We also observed such high
frequency of gastrointestinal epithelial tumors being diagnosed
simultaneously with GIST, actually one in every 8 patients with
GIST in our series presented a synchronous epithelial tumor, most
of them in the stomach, colon and esophagus.hronous primary tumor
Localization Size (cm)
ocarcinoma (T3N0M0) Colon 5.5
ocarcinoma (T3N1M0) Gastric 10.2
ocarcinoma (T3N1M0) Gastric 4.8
inoma epidermoid (T3N2M0) Esophagus 4.6
ocarcinoma (T3N0M0) Colon 5.8
sive ductal carcinoma (T3N1M0) Breast 6.2
Table 3
Histopathologic features of the synchronous GISTs.
Patient number CD117 CD34 S-100 SMA Desmin AE1/AE3 PDGF Tumor size (cm) Mitotic index
(x/50 hpf)
Risk category for
malignant behavior20
1 þ þ e þ e e e 5.0 >20 High
2 þ þ þ þ þ e e 1.1 <5 Very low
3 þ þ þ þ e e e 0.7 <5 Very low
4 þ þ þ þ þ e e 0.7 <5 Very low
5 þ þ e e e e e 5.0 >20 High
6 þ þ e e e e e 7.6 <5 Intermediate
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kit protein) and CD34 (hematopoietic cell progenitor antigen).27
The majority of GISTs are usually positive for CD117 (near 95%
of cases) and CD34 (positive in 40% of cases). Few cases present
positivity for S-100 (positive near 5% of cases) and desmin
(positive in approximately 2% of cases).20,28e31 Simultaneous
detection of CD117/CD34 is not a feature observed in the majority
of GIST tumors, but curiously, in all of our six patients with
synchronous tumors the immunohistochemical staining for CD117
and CD34 proteins was positive. Another interesting observation
regards to the independence of the stage of the disease and
synchronicity. In our series, synchronicity was not related to the
aggressiveness of GIST even low grade cases were found with
synchronic tumors in our group of patients suggesting that the
development of a second neoplasia (being GIST or carcinoma) can
be a very early event in these individuals. The high frequency of
synchronous GIST and adenocarcinoma rises some questions in
regard to the origin of both neoplasias. It is conceivable that at
least some cases of GIST arise from a progenitor cell capable to
differentiate either to mesenchymal and epithelial lineages.19,32 It
is interesting to observe that all patients with synchronous GIST
in our series expressed CD34, a well-known marker of precursor
cells.27 Another possibility to explain synchronicity is that the
environmental carcinogens might affect molecular pathways that
are shared by mesenchymal and epithelial cells of the digestive
tract.33,34
In summary, the synchronous occurrence of GISTs and other
primary tumors is more common than it has been considered and
usually they are discovered incidentally during the surgery per-
formed because of the other malignancy. More assertive search for
GIST in the digestive tract of patients with adenocarcinoma may
reveal an even larger number of cases. Further studies are
required to clarify the molecular and genetic mechanisms of
carcinogenesis and progression associating GIST and synchronous
tumors.Conﬂict of interest
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